What Is PD-L1? A Clear Guide to Its Role in Cancer Immunity

A transmembrane protein anchored on the surface of certain cells binds PD-1 on T cells and delivers an off signal that shuts down immune attacks. When tumor cells display large amounts of this protein, they tell your patrolling T cells to stand down rather than attack. A pathology test that measures PD-L1 expression on a tumor sample helps you and your oncologist decide whether immune checkpoint inhibitors are likely to work for your situation.

This guide walks through the biology behind PD-L1, how tumors exploit it to hide from your immune system, and what lab measurements actually mean for treatment planning.

The Basic Biology of PD-L1 and How It Regulates Immune Responses

Discovered in the late 1990s under the name B7-H1, programmed death-ligand 1 helps cells manage immune activity through PD-1 binding. Healthy cells across many tissues express it on their outer membrane, where it serves as a polite request to your nearby immune cells: don’t attack me, I’m part of the body.

The handshake happens at a partner protein called PD-1, or programmed cell death protein 1, which sits on your activated T cells. When PD-L1 docks into PD-1, it sends an off signal that quiets the T cell, prevents it from multiplying, and eventually pushes it toward T-cell exhaustion. Under normal conditions, this checkpoint prevents autoimmune damage and protects your tissues from friendly fire during infection.

Where PD-L1 Shows Up in Your Body

Outside of cancer, low levels of PD-L1 appear on placental cells, on cells lining your lung airways, and on certain patrolling immune cells. The protein’s job in those spots is tolerance. A placenta carrying a fetus needs to avoid rejection, and your lung tissue breathes in irritants daily, so it benefits from a built-in peacekeeper.

Tumors borrow that same peacekeeper. Many solid cancers, including lung, breast, skin, bladder, and head and neck tumors, decorate their outer surface with PD-L1 and use it to defend against immune attack. The tumor microenvironment, which includes macrophages and dendritic cells, often stains positive too, and that immune cell staining can matter just as much as the tumor’s own signal when your team is evaluating a report.

Why Tumors Hijack the PD-1 Pathway to Evade Destruction

Tumor cells don’t invent PD-L1 from scratch. They co-opt a normal tolerance pathway and amplify it, turning a healthy safeguard into a survival shield. Understanding how this happens sets up everything that follows about testing and the treatment choices you may face.

Adaptive Resistance Through Interferon-Gamma

One driver is interferon-gamma, a chemical messenger released by T cells during an immune attack. Paradoxically, this same signal, meant to rally the immune system, can trigger nearby tumor cells to crank up their PD-L1 production. The result is a feedback loop. T cells arrive, tumor cells respond by putting on more PD-L1, and the T cells are turned off before they finish the job.

This adaptive resistance shows up most clearly in tumors under active immune pressure. A melanoma that started making PD-L1 only after T cells arrived behaves differently from one that produced PD-L1 from day one, and that timing can influence how well checkpoint drugs work for you if your tumor fits either pattern.

A Hallmark of Tumor Survival

Pathologists now consider immune evasion through the PD-1/PD-L1 axis one of the established hallmarks of cancer, a framework formalized in landmark reviews across the field. A tumor that survives despite a strong T-cell response has usually found a way to neutralize those T cells, and blocking PD-1 or PD-L1 directly removes the shield. That mechanism explains why a single protein can reshape an entire field of cancer immunotherapy.

The brake is consistent across many cancer types, even when the cancers themselves look nothing alike on a scan.

Measuring PD-L1 Expression With Immunohistochemistry Assays

Detecting PD-L1 in a patient sample uses immunohistochemistry, or IHC, the same staining technique pathologists use to classify breast cancer or lymphoma. A thin slice of your tumor tissue is treated with antibodies that latch onto PD-L1, then with a colored enzyme that marks where the antibody bound. The stained slide is reviewed under a microscope, and the percentage of stained cells determines the score on your report.

The Three Scoring Systems Pathologists Use

Three scoring approaches dominate clinical practice, and each was developed alongside a specific drug’s clinical trials. None of them are interchangeable, which trips up many patients who assume a “positive” result means the same thing everywhere.

A TPS of 50 in lung cancer, meaning half the tumor cells stain positive, is a strong signal. A CPS of 10 in head and neck cancer counts tumor cells plus surrounding lymphocytes and can suggest benefit even when the tumor cells themselves look quiet. Always confirm which score your report uses, because the cutoff thresholds shift depending on the system.

PD-1 Inhibitors Versus PD-L1 Inhibitors and How They Differ

The two drug classes both release the brake on T cells but bind different halves of the checkpoint. Knowing the difference matters because approved uses and the companion diagnostic tied to each drug are not always the same.

Anti-PD-1 Antibodies Target the T-Cell Side

Drugs such as pembrolizumab (Keytruda) and nivolumab (Opdivo) bind the PD-1 receptor on your T cells. By covering the receptor, they prevent PD-L1 from delivering its off signal, even if the tumor keeps producing PD-L1. Most non-small cell lung cancer regimens use this class in the first line, with pembrolizumab tied to the 22C3 pharmDx assay on the Dako platform.

Anti-PD-L1 Antibodies Target the Tumor Side

Monoclonal antibodies such as atezolizumab (Tecentriq), durvalumab (Imfinzi), and avelumab block PD-L1 directly on tumor cells and immune cells. Each uses its own antibody clone: SP142 for atezolizumab in some contexts, SP263 for durvalumab, and 73-10 for avelumab. Because the clones recognize slightly different parts of the PD-L1 protein, results from one assay do not automatically transfer to another. A lab that runs only one clone cannot report the others without specific validation for your case.

A clinical report is only as portable as the assay behind it, which is why clone-specific validation matters before any drug decision is made.

“The same patient can be reported as “high” on one assay and “low” on another, depending on the antibody clone used. Always ask which clone produced your number.

Cancer Types Where PD-L1 Status Guides Your Treatment Decisions

Oncologists order the test for several tumor types, yet the percentage score that leads to a specific regimen changes from one cancer to the next. The four cancers below illustrate how scores translate into real choices you may face at the clinic.

Non-Small Cell Lung Cancer

Lung cancer remains the most established setting for PD-L1 testing. A TPS of 50 or higher qualifies many patients for pembrolizumab monotherapy as first-line treatment, while a TPS of 1 to 49 typically leads to pembrolizumab combined with platinum chemotherapy. Patients with a TPS below 1 still receive chemoimmunotherapy combinations in many cases, because chemotherapy can release additional antigens that complement your immune response.

Head and Neck Squamous Cell Carcinoma

Head and neck cancer uses CPS instead of TPS. A CPS of 1 or higher supports pembrolizumab use, often combined with chemotherapy in the recurrent or metastatic setting. Higher CPS values, generally 20 and above, predict stronger single-agent responses, so your oncologist may lean toward monotherapy when your number sits in that range.

Urothelial, Gastric, and Triple-Negative Breast Cancers

Urothelial carcinoma of the bladder historically used the IC score with atezolizumab, though practice patterns have shifted with newer data. Gastric and gastroesophageal junction cancers use CPS, with a threshold of 5 commonly cited for pembrolizumab. Triple-negative breast cancer uses CPS as well, with a threshold of 10 guiding whether pembrolizumab joins chemotherapy in your metastatic setting.

Where the Score Falls Short

Some patients with low or even negative PD-L1 expression still derive meaningful benefit, especially when checkpoint inhibitors are paired with chemotherapy. Conversely, a high score does not guarantee a response. Tumor heterogeneity, prior therapy, and other immune markers all influence your outcome, so treat the score as a probability guide rather than a yes-or-no gate.

Limitations of PD-L1 as a Biomarker and What Test Results Cannot Tell You

Thousands of patients have benefited from a test that still gives only a partial picture of tumor immune behavior. Four honest limits deserve attention before you interpret a number as destiny.

PD-L1 Expression Changes Over Time and Space

A biopsy captures one moment in one tumor site. PD-L1 levels can shift between the primary tumor and a metastasis, between an untreated lesion and one exposed to chemotherapy or radiation, and even between two areas of the same tumor. A sample from your lung may give a different number than a sample from a liver metastasis months later, which is why repeat biopsies sometimes appear in your treatment plans.

Tumor Heterogeneity Skews a Single Biopsy

Tumors are not uniform. A core needle biopsy samples only a sliver of tissue, and PD-L1 expression can vary from one region to another. Small biopsies and fine-needle aspirates are especially prone to missing high-expression pockets, which is why some guidelines recommend sampling the most accessible, viable tumor site when possible for you.

Cutoffs Vary by Drug and Indication

A TPS of 1 in lung cancer carries one meaning, while a CPS of 1 in head and neck cancer carries another. Even within lung cancer, thresholds have shifted as data have matured, with 50 replacing older 25 cutoffs for some regimens. Applying one universal rule across cancer types, or even across drugs for the same cancer, is not safe when you weigh your options.

Other Immune Biomarkers Also Matter

Tumor mutational burden, microsatellite instability, and gene expression signatures all add information beyond a single protein score. Tumor mutational burden (TMB), which measures how many mutations your tumor carries, and microsatellite instability (MSI) status predict response to checkpoint inhibitors in many cancer types. Some tumors with low PD-L1 but high TMB respond well, while some tumors with high PD-L1 but low TMB do not.

Many oncologists now consider multiple biomarkers together rather than relying on PD-L1 in isolation, so you may be offered TMB or MSI testing alongside it.

Bottom Line

A single protein on tumor cells can drive major treatment choices in oncology because it lets cancers flip an immune off switch. A stained slide that quantifies that protein helps your oncologist weigh checkpoint inhibitors, but the score is one piece of a larger puzzle. Asking which assay was used, what threshold applies to your cancer type, and whether other biomarkers were tested alongside it turns a number into an informed conversation.

FAQ